Annual report [Section 13 and 15(d), not S-K Item 405]

Significant Strategic Collaborations (Details Narrative)

Significant Strategic Collaborations (Details Narrative) - USD ($) shares in Millions		12 Months Ended
	Mar. 17, 2023	Dec. 31, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		$ 2,500,284	$ 2,539,986
Research and development expenses		3,288,332	3,494,765
Advance payment and included within prepaid expenses and other current assets		421,954	603,828
Liability and included in accrued expenses and other current liabilities		$ 34,203	$ 48,256
Pharmsynthez [Member] \| Series B Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants outstanding		1.5
Pharmsynthez [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent ownership in Xenetic		3.40%	3.40%
Volition [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses		$ 26,000
Takeda [Member] \| Royalty Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		2,500,000	$ 2,500,000
Catalent Pharma Solutions [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses		2,500,000
Advance payment and included within prepaid expenses and other current assets		28,000	100,000
Liability and included in accrued expenses and other current liabilities		100,000
Other assets		300,000	300,000
Scripps Research [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses	$ 900,000
Scripps Research [Member] \| Scripps Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses		900,000
Prepaid expenses and other		400,000
University Of Virginia [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses		400,000	$ 0
Advance payment and included within prepaid expenses and other current assets		$ 100,000